Edwin M. Posadas, MD

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.

Effectively, the field has tested agents for metastatic disease in only two clinical settings: primary management of metastatic disease (first-line) and after progression with a first-line therapy (second-line); however, there are no category 1 data that support the use of any agent in the third-line setting.